AU2012311542B2 - Screening methods and uses thereof - Google Patents

Screening methods and uses thereof Download PDF

Info

Publication number
AU2012311542B2
AU2012311542B2 AU2012311542A AU2012311542A AU2012311542B2 AU 2012311542 B2 AU2012311542 B2 AU 2012311542B2 AU 2012311542 A AU2012311542 A AU 2012311542A AU 2012311542 A AU2012311542 A AU 2012311542A AU 2012311542 B2 AU2012311542 B2 AU 2012311542B2
Authority
AU
Australia
Prior art keywords
ligand
ligands
target
construct
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012311542A
Other languages
English (en)
Other versions
AU2012311542A1 (en
Inventor
Bjorn Frendeus
Jenny MATTSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Publication of AU2012311542A1 publication Critical patent/AU2012311542A1/en
Application granted granted Critical
Publication of AU2012311542B2 publication Critical patent/AU2012311542B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
AU2012311542A 2011-09-22 2012-09-20 Screening methods and uses thereof Active AU2012311542B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1116364.9A GB201116364D0 (en) 2011-09-22 2011-09-22 Screening methods and uses thereof
GB1116364.9 2011-09-22
PCT/EP2012/068576 WO2013041643A1 (en) 2011-09-22 2012-09-20 Screening methods and uses thereof

Publications (2)

Publication Number Publication Date
AU2012311542A1 AU2012311542A1 (en) 2014-03-20
AU2012311542B2 true AU2012311542B2 (en) 2017-09-21

Family

ID=44937671

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012311542A Active AU2012311542B2 (en) 2011-09-22 2012-09-20 Screening methods and uses thereof

Country Status (18)

Country Link
US (1) US10191049B2 (da)
EP (1) EP2758532B1 (da)
JP (2) JP6370220B2 (da)
KR (1) KR102024125B1 (da)
CN (2) CN103827302A (da)
AU (1) AU2012311542B2 (da)
CA (1) CA2848932C (da)
DK (1) DK2758532T3 (da)
ES (1) ES2690783T3 (da)
GB (1) GB201116364D0 (da)
HK (1) HK1200486A1 (da)
HU (1) HUE040567T2 (da)
IN (1) IN2014DN01795A (da)
PL (1) PL2758532T3 (da)
PT (1) PT2758532T (da)
RU (1) RU2622089C2 (da)
SI (1) SI2758532T1 (da)
WO (1) WO2013041643A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2392723B (en) 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof
JP6465407B2 (ja) * 2013-11-22 2019-02-06 株式会社Molcure 標的分子に結合するポリペプチドの決定方法及び決定システム
EP3177924B1 (en) 2014-08-07 2020-01-08 The General Hospital Corporation Stabilization of whole blood samples
CN109651506B (zh) * 2017-10-11 2021-12-07 上海交通大学 一种快速获得抗原特异性抗体的方法
WO2023242125A1 (en) * 2022-06-13 2023-12-21 Bioinvent International Ab Methods of isolating anti-ligands

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004023140A1 (en) * 2002-09-04 2004-03-18 Bioinvent International Ab Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands
WO2004101790A1 (en) * 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2009079793A1 (en) * 2007-12-21 2009-07-02 National Research Council Of Canada Non-aggregating human vh domains

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366862A (en) 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
ATE160818T1 (de) 1990-06-01 1997-12-15 Chiron Corp Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
WO1995017907A1 (en) 1993-12-27 1995-07-06 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions for inhibiting thrombogenesis
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
AU770952B2 (en) 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
WO2002039120A1 (en) 2000-11-09 2002-05-16 Bionova Pharmaceutials, Inc. A method for identifying the proteome of cells using an antibody library microarray
CN101333243A (zh) * 2003-05-14 2008-12-31 多曼蒂斯有限公司 从多肽全能文库恢复可逆可解折叠多肽的方法
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004023140A1 (en) * 2002-09-04 2004-03-18 Bioinvent International Ab Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands
WO2004101790A1 (en) * 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2009079793A1 (en) * 2007-12-21 2009-07-02 National Research Council Of Canada Non-aggregating human vh domains

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOEL, E. et al., Infection and Immunity, 1998, vol. 66, no. 1, pages 83-88 *
SHINOHARA, N. et al., Journal of Immunological Methods, 2002, vol. 264, pages 187-194 *
SHINOHARA, N. et al., PNAS, 2000, vol. 97, no. 6, pages 2585-2590 *
WILLIAMS, B. R. et al., Immunology Letters, 2002, vol. 81, pages 141-148 *

Also Published As

Publication number Publication date
EP2758532B1 (en) 2018-07-11
JP6370220B2 (ja) 2018-08-08
PL2758532T3 (pl) 2018-12-31
KR102024125B1 (ko) 2019-09-23
US20140227249A1 (en) 2014-08-14
CN107663238A (zh) 2018-02-06
EP2758532A1 (en) 2014-07-30
IN2014DN01795A (da) 2015-05-15
CA2848932C (en) 2020-12-29
GB201116364D0 (en) 2011-11-02
JP2018154627A (ja) 2018-10-04
HK1200486A1 (en) 2015-08-07
DK2758532T3 (da) 2018-10-22
KR20140080504A (ko) 2014-06-30
CN103827302A (zh) 2014-05-28
PT2758532T (pt) 2018-11-07
JP2015501289A (ja) 2015-01-15
RU2622089C2 (ru) 2017-06-09
CA2848932A1 (en) 2013-03-28
US10191049B2 (en) 2019-01-29
AU2012311542A1 (en) 2014-03-20
HUE040567T2 (hu) 2019-03-28
SI2758532T1 (sl) 2018-12-31
WO2013041643A1 (en) 2013-03-28
RU2014115956A (ru) 2015-10-27
ES2690783T3 (es) 2018-11-22

Similar Documents

Publication Publication Date Title
AU2012311542B2 (en) Screening methods and uses thereof
JP4564062B2 (ja) 抗体ライブラリーをスクリーニングする方法
US10351970B2 (en) Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands
CN107430130B (zh) 方法
KR20140027915A (ko) 단일 세포 내 생체 분자의 동시 검출
JP4729043B2 (ja) 抗体ライブラリーをスクリーニングする方法
Hensen et al. Multiplex peptide-based B cell epitope mapping
WO2023242125A1 (en) Methods of isolating anti-ligands
Hung et al. Phage Display for Imaging Agent Development

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)